Bexion Pharmaceuticals, LLC, is doing amazing things in the fight against pancreatic cancer and the Kentucky Cabinet for Economic Development (KCED) is taking notice.
an effort to help this pancreatic cancer research along, the KCED has
awarded SBIR-STTR Matching Funds of $99,965 to Bexion for their National Institutes of Health (NIH) grant called "A Novel Biotherapeutic Treatment for Pancreatic Cancer."
Alongside the KCED, Northern Kentucky Tri-ED's Northern Kentucky ezone and the KCED's Department of Commercialization (DCI) are also lending a helping hand to Bexion.
Kentucky is in the early stages of becoming a significant contributor
to Kentucky’s future in bioscience with Bexion’s presence and the
additional companies that will come to the area as a result of this
company’s success," says Chairman of NKY Tri-Ed and Kenton County Judge
Executive, Ralph Drees.
Bexion is gaining notoriety for a promising piece of preclinical anti-tumor technology from Cincinnati Children's Hospital Medical Center.
new protein-lipid nanovesicle technology attacks tumors in cases of
glioma, pancreatic cancer, neuroblastoma and leukemia, and selectively
kills cancer cells, while leaving healthy cells unscathed.
being a boon for cancer victims, this new technology holds great
promise for the Kentucky's flourishing medical research industry.
is a very promising addition to Kentucky’s growing and emerging life
science portfolio of companies," says DCI Commissioner Deborah
Clayton. "The Commonwealth’s unique SBIR-STTR matching program is a
valuable resource available to high-tech companies located in the state
or willing to relocate here."
KCED's assistance to Bexion has been received with gratitude.
a clear statement of appreciation, Bexion CEO Dr. Ray Takigiku says,
"Bexion’s mission is to develop cures for cancer, and Kentucky’s
programs are helping us by providing a much needed mechanism to
increase our resources to more rapidly bring our first product into the
clinic and help patients… These Kentucky programs clearly support us."
Writer: Jonathan DeHart
Source: Cheryl Besl, Kentucky Cabinet for Economic Development, Bexion Pharmaceuticals, LLC